These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32201923)

  • 1. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction.
    Kamarajah SK; Navidi M; Wahed S; Immanuel A; Hayes N; Griffin SM; Phillips AW
    Ann Surg Oncol; 2020 Sep; 27(9):3182-3192. PubMed ID: 32201923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
    Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction.
    Mine S; Watanabe M; Kumagai K; Okamura A; Yuda M; Hayami M; Yamashita K; Imamura Y; Ishizuka N
    Dis Esophagus; 2019 Dec; 32(11):. PubMed ID: 30791046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment.
    Sisic L; Blank S; Nienhüser H; Dorr S; Haag GM; Jäger D; Bruckner T; Müller-Stich BP; Ott K; Büchler MW; Ulrich A; Schmidt T
    Eur J Surg Oncol; 2018 Oct; 44(10):1646-1656. PubMed ID: 30082176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
    Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
    Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma.
    Kamarajah SK; Markar SR; Low D; Phillips AW
    BJS Open; 2023 May; 7(3):. PubMed ID: 37341158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of neoadjuvant downstaging in gastric adenocarcinoma.
    Prasad P; Sivaharan A; Navidi M; Fergie BH; Griffin SM; Phillips AW
    Surgery; 2022 Aug; 172(2):593-601. PubMed ID: 35400501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.
    Rao T S; Raju KVVN; Patnaik SC; Reddy P; Saksena AR; Rajappa S; Mallavarapu KM; Santa A; Gudipudi D; Boleneni N; Usofi Z; Gujjuru S; Smith L; Are C; Nusrath S
    J Surg Oncol; 2021 Jun; 123(7):1547-1557. PubMed ID: 33650697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
    Rice TW; Ishwaran H; Kelsen DP; Hofstetter WL; Apperson-Hansen C; Blackstone EH;
    Dis Esophagus; 2016 Nov; 29(8):906-912. PubMed ID: 27905170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery : early results and toxicity.
    Leibl BJ; Vitz S; Schäfer W; Alfrink M; Gschwendtner A; Grabenbauer GG
    Strahlenther Onkol; 2011 Apr; 187(4):231-7. PubMed ID: 21437768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
    Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
    Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
    [No Abstract]   [Full Text] [Related]  

  • 18. Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
    Kobayashi K; Kanetaka K; Yoneda A; Kobayashi S; Maruya Y; Isagawa Y; Yoshimoto T; Migita K; Kawaguchi Y; Kuba S; Morita M; Okada S; Kosaka T; Yamaguchi S; Inoue Y; Adachi T; Hidaka M; Torashima Y; Ito S; Takatsuki M; Eguchi S
    J Gastrointest Cancer; 2021 Jun; 52(2):582-592. PubMed ID: 32524305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma.
    Raja S; Rice TW; Murthy SC; Ahmad U; Semple ME; Blackstone EH; Ishwaran H;
    Ann Surg; 2021 Oct; 274(4):e320-e327. PubMed ID: 31850981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.